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ABSTRAK
Rheumatoid arthritis (RA) adalah bentuk kronis peradangan persisten. Sementara itu, substansi P adalah neuropeptida yang paling
terkait dalam inflamasi neurogenik dan hiperalgesia umumnya ditemukan dalam penyakit kronis. Substansi P bertindak sebagai
pengikat neurokinin-1 reseptor. Penelitian ini dilakukan untuk mengevaluasi efek dari neurokinin-1 antagonis reseptor (CP-96345)
pada model tikus induksi artritis, yang diinduksi oleh Complete Freund Adjuvant (CFA). Tujuannya adalah untuk melemahkan
inflamasi neurogenik yang pada gilirannya akan meningkatkan waktu latency hiperalgesia respon, menurunkan ekspresi neurokinin-
1 reseptor, dan menghambat perkembangan RA dalam model tikus AIA. Tikus intra-articularly disuntik dengan CFA 1 jam setelah
administrasi CP-96345 baik dengan 0,63 ug / gr; 1,25 ug / gr; atau 2,5 mg / gr juga intra articularly. Pengukuran Caliper dan uji
hot-plate dilakukan pada hari 0, 3, 5, 7, 9, 11, dan hari 13. Ekspresi neurokinin-1 reseptor di jaringan sendi dievaluasi oleh
imunohistokimia, dan RA kemajuan dalam jaringan sendi yang diamati hystopathologically. CP-96345 sebesar 2,5 ug / gr
significantly meningkatkan latency dari hiperalgesia waktu respon pada tikus CFA diinduksi (p = 0,044) dan menurunkan
neurokinin-1 ekspresi reseptor di jaringan sendi (p = 0,029) dibandingkan dengan CFA diinduksi tikus. Tidak ada perbedaan
significant untuk pengukuran caliper dan kemajuan RA antara CFA incduced tikus dan kelompok perlakuan. Meyakinkan, CP-96345
meningkatkan latency waktu respon hiperalgesia dan mengurangi NK-1 ekspresi reseptor di tikus bersama tapi tidak bisa
menghambat perkembangan RA. (FMI 2016;52:87-93)
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ABSTRACT
Rheumatoid arthritis (RA) is a chronic form of persistent inflammation. Meanwhile, Substance P is the most associated neuropeptide
in neurogenic inflammation and hyperalgesia commonly found in chronic pain. Substance P act by binding to neurokinin-1 receptor.
The present study was conducted to evaluate the effect of neurokinin-1 receptor antagonist (CP-96,345) on Adjuvant Induced
Arthritis rat model, induced by Complete Freund’s Adjuvant (CFA). The objective is to attenuate neurogenic inflammation which in
turn will increase the latency time of hyperalgesia response, decreases neurokinin-1 receptor expression, and inhibits the
development of RA in AIA rat model. Rats were intra-articularly injected with CFA 1 hour after the administration of CP-96,345
either by 0.63 µg/gr; 1.25 µg/gr; or 2.5 µg/gr also intra-articularly. Caliper measurements and hot-plate test were performed on day
0, 3, 5, 7, 9, 11, and day 13. Expression of neurokinin-1 receptor in joint tissue were evaluated by immunohistochemistry, and RA
progress in joint tissue were observed hystopathologically. CP-96,345 at 2.5 µg/gr significantly increases the latency of hyperalgesia
response time on CFA induced rats (p=0.044) and decreased the neurokinin-1 receptor expression in joint tissue (p=0.029)
compared to CFA induced rats. There was no significant difference for caliper measurements and RA progress between CFA
incduced rats and treated group. Conclusively, CP-96,345 increases the latency of hyperalgesia response time and decreases the
NK-1 receptor expression in rat joint but could not inhibit RA progression. (FMI 2016;52:87-93)
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INTRODUCTION
Chronic pain (neuropathic pain) occurs when there is
trauma in the nervous system as seen in rheumatoid
arthritis (RA) (Inoue et al 2013), which is a chronic
form of inflammation (Vashist et al 2012, Aggarwal &
Myles 2013, Emery 2011). The most common symptom
of neurophatic pain includes spontaneus pain,
hyperalgesia, and allodynia (Inoue et al 2013).
Treatment with NSAID’s in RA is not ideal because of
its longterm side effect. DMARD’s and TNF- Inhibit-
ors therapy now had become popular (Emery 2011).
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Even then, pain still become the main symptom that
could not be controlled properly (Breedveld & Kalden
2004, Lee & Hasset 2011). This indicates there is
another factor playing role in the development of
chronic pain in RA (Lee & Hasset 2011). Neurogenic
inflammation had been repeatedly suggested to play
important role in chronic inflammation (Richardson &
Vasko 2002, Johnson & Bolay 2005, Ren & Dubner
2010, Peterson et al 2013). Substance P is the most
associated with neurogenic inflammation and hyper-
algesia (Richardson & Vasko 2002, Davis & Perkins
1996, Bhatia et al 2009, Brain & Keeble 2004). SP can
be released when there is a repeated stimulation on the
neurons (Geppeti et al 2006, Dickenson 1999) and act as
a potent pro-inflammatory agent (O'Connor et al 2004)
inducing inflammation pathway other than those that
already exists. Therefore creating redundancy between
neuro-immune interaction where the inflammation
process is maintained and prolonged (O'Connor et al
2004, Cases et al 2005, Reedquist & Tak 2012, Austin
& Taylor 2010, Aloisi & Bonifazi 2006). SP act by
binding to neurokinin-1 (NK-1) receptor (Krause et al
1992). The tachykinins, through acting on NK-1
receptors have been long suspected to play a role in
acute and neurogenic inflammation (Han et al 2002,
Peterson et al 2013, Hallin et al 1992, Friess et al 2001)
and have been well documented in tendons with chronic
pain (Peterson et al 2013). Meanwhile, not many data
available on how the role of NK-1 in the management of
pain where SP is bound to be released (e.g in RA),
instead of being injected to induce the hyperalgesia
response (Davis & Perkins 1996, Teodoro et al 2013).
In this study, we explore the possibility of using NK-1
receptor antagonist as a local analgesic in the
management of chronic pain associated with




Animal used in the present study were 6 to 8 week-old
male Wistar rats weighing 150-200 g. Rats were housed
in single cages with 12 h light-dark cycles for 1 week
before the experiments. Water and food were available
and can be accessed freely. All experimental procedures
were approved by Animal Care and Use Committee of
Veterinary Medicine Faculty, Universitas Airlangga,
Indonesia (Approval number; 434-KE).
Animal Model
To obtain rheumatoid arthritis model, rats were injected
with 25 µl of CFA (Sigma-Aldrich) solution into the
tibiofemoral joint of the right hind leg under propofol
anesthesia (10 mg/kg.i.v) using microsyringe with a 26-
G needle (referred to as day 0). CFA solution were
vortex-mixed before each injection. A control group
was assigned and injected with salin with the same
volume.
Drug administration
1 h prior to CFA injection, the rats were anesthetized
with i.v propofol (10 mg/kg) and NK-1 receptor
antagonist CP-96,345 (Sigma-Aldrich) either 0.63 µg/g;
1.25 µg/g; or 2.5 µg/g were administered intra-articular-
ly using microsyringe and a 30-G needle. CP-96,345
were dissolved in solution of 40% DMSO and 60%
salin. A control group was assigned with the injection of
only the vehicle.
Behavioral Examination
Hyperalgesia response was tested on day 0 (before any
treatment), and then on day 5, 7, 9, 11, and day 13 using
hot-plate instrument (Ugo Basile) with 30 sec cut off
time. The 3rd day of examination point was skipped as
the rats were left immobile due to the severe swelling on
their joint. Rat were placed on the plate and nociceptive
responses were observed either for paw licking, rearing,
tapping, straightening or jumping off. The time needed
for rat to initiate nociceptive responses were recorded as
hyperalgesia latency time.
Assesment of physiological parameters for
inflammation
Caliper measurements were conducted prior to any
treatment on day 0, and then on day 3, 5, 7, 9, 11, and
day 13 to detect any swelling of the tibiofemoral joint.
The space between medial and lateral meniscus of the
affected joint were measured with feret method using
vernier caliper.
Histological analysis
On day 13th after the last observation, rats were
anesthetized with i.v propofol (10 mg/kg) and then
blood were drained transcardially. The tibiofemoral
joint were dissected out and fixated in 4% paraform-
aldehyde at room temperature overnight. Tissue were
then decalcified in 10% EDTA (Merck) solution (pH
7.4) for 4 weeks and cut into cross sections. The
sections were stained with 1% hematoxylin (Merck) for
3 min. Image from stained sections were captured with a
CX 22 microscope equipped with digital camera
(Olympus).
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Immunohistochemistry analysis
Prepared tissue sections were deparafinized by washing
with xylol 3x5 min, and then by alcohol 5 min each of
100%, 95%, and 80%, and then lastly in PBS for 3x5
min. sections incubated in 10% of hydrogen peroxidase
for 5 min, and antigen retrieval were performed using
ready-to use DIVA decloaking solution (Biocare Medic-
al) and microwaved (domestic microwave) for 10 min,
all the while keeping the buffer solution level. Sections
were incubated in primary antibody NK-1 receptor bs-
0064R (Bioss) overnight at 4°C and then in secondary
antibody simple strain rat mas PO (Bioss) for 30 min at
room temperature. Chromogen were added using DAB
solution for 20 min at room temperature and counter-
stained using hematoxylin-eosin solution for 5 min.
Tissue sections were rehydrated and ready for mount-
ing. Image from stained sections were captured using a
CX 22 microscope equipped with digital camera
(Olympus).
8 Statistical Analysis
Values were expressed as means ± SD. Effect of CP-
96,345 on hyperalgesia response and caliper measure-
ments were analyzed by two-way analysis of variance
(ANOVA) repeated measurements, followed by
individual post hoc multiple comparisons (Tukey test).
The expression of NK-1 receptor were counted using
Allred scoring method, and the values were analyzed by
non-parametric analysis (Kruskall-Wallis) followed by
Mann-Whitney post hoc multiple compar-ison tests.
Values of p<0.05 were considered to be statistically
significant.
RESULTS
Time course of the mechanical hyperalgesia and
caliper measurements on CFA induced rats
The latency time of hyperalgesia response on day 5 both
CFA induced and control group were decreased
compared to day 0. On day 7 onward, control group
values gradually reversed back reaching its initial
latency time while the latency time on CFA induced
group were continued to shorten. The values were
analized on both groups at corresponding days by two
way ANOVA repeated measure (p = 0.019) and the
difference were seen to occur on day 9 (p = 0.022).
CFA-induced group showed significant increase in the
length of caliper measurements on day 3rd (p = 0.006)
compared to control group. Although it is not
significantly different on day 5, 7, 9, and 11, the values
were constantly above the control group and peaked
again on day 13th and was considered significanty
different (p = 0.021).
Effect of CP-96,345 on CFA induced rats
The injection of CP-96,345 prior to the CFA injection
apparently could not inhibit the swelling formed on day
3. All treated group have increased caliper measure-
ments as seen in CFA induced rats (Fig.1)
Fig.1 By two-way ANOVA-RM analysis, all CP-96,345
treatment groups were compared to control and
CFA induced rats. There was no statistically
different mean value observed (p = 0.052).
On the other hand, injection of CP-96,345 showed
significant effect on increasing the latency time of hot-
plate test. All 3 of treated group have increased latency
time compared to the CFA induced rats model group,
showing dose dependent manner (Fig.2).
Fig. 2 Effect of CP-96,345 administration on CFA
induced hyperalgesia response. By two-way
ANOVA-RM analysis, there was statistically
different mean value observed at p= 0.029.
Dunnet’s post hoc analysis for multiple
comparison were then performed, and CP-
96,345 at 2.5 µg/g was considered statistically
different compared to CFA induced rats (p =
0.022). Further Tukey’s analysis revealed the
difference occured on day 13th (p=0.044).
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Fig. 3 H-E staining on joint tissue cross-sections. CFA induced rat (A) magnified 40x and (B) magnified 100x.
Compared to control (C) magnified 40x and (D) magnified 100x. Hyperplasia of synovial lining can be seen in
the joint of CFA induced rat, noted by the black arrow, where as the control group still have normal synovial
lining. Under the synovial lining, cartilage erosion can also be observed, where as the control group cartilage
remained compact.
Fig. 4. NK-1 receptor Immunoreactivity (brown stain) on synovial membrane of CFA induced rat, noted by yellow
arrows. (A), and treated rat with CP-96,345 either by 0.63 µg/gr (B); 1.25 µg/gr; or 2.5 µg/gr (D). All
magnified100x.
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Hystological findings on the joint
By hematoxylin-eosin staining, the joint tissue from rats
group were examined under microscope. CFA induced
rats showed RA characteristics (Fig.3) with visible pro-
liferation, pannus formation, and hyperplasia of the
synovial lining. CP-96,345 injection could not alter the
progress of this joint destruction as all of treated group
also showed the same RA characteristics (data not
shown).
Expression of NK-1 receptors in the joint
All treatment group and CFA induced group showed
NK-1 activity with different intensities by immuno-
histochemistry staining (Fig.4). The expressions were
evaluated by Allred scoring method. The expression of
NK-1 receptor also showed dose dependent manner of
CP-96,345 injected. CFA induced rats showed high
intensity of NK-1 receptor expression, and the treated
group showed diminished intensity as CP-96,345
concentration gets higher.
DISCUSSION
On present study, we note the effect of NK-1 receptor
antagonist on attenuating hyperalgesia response in CFA
induced rat of RA model. Rheumatoid arthritis occurs
after persistent joint inflammation that triggers edema,
vascular remodelling and cellular infiltration. SP
triggers inflammation condition by inducing cytokines
and chemokines expressions such as macrophage in-
flammatory protein-1 (MIP-1) and monocyte chemo-
tactic protein-1 (MCP-1) through NF-kb path-way. SP
also increases neutrophil recruitment and adhesion
process by triggering the upregulation of chemokines
receptors (Bhatia et al 2012).
Substance P act by binding to neurokinin-1 (NK-1)
receptor and leads to longer depolarization time by
activating K+ current or by increasing Na+ or Ca+
currents. NK-1 antagonis can block this spinal response
initiation, and reduces further signaling pathway
triggered by N-methyl-D-aspartate (NMDA) receptors.
As have been understood, activation of alpha-amino-3-
hydroxy-5-methyl-isoxazole (AMPA) receptors is
associated with acute inflammation response, while
NMDA receptors were associated with repeated
stimulation of C fiber. Thus amplifying the neurons
responses, prolonging the response and believed to have
caused hyperalgesia (Dickenson 1999, Gerhardt &
Schmidtko 2011).
To confirm the RA model in rat, caliper measurements
were conducted to asses the inflammation on affected
joint. As expected, on day 3 the swelling occured on
CFA induced rat (p = 0.006) compared to control. The
adaptif immune response occur on day 3-7 when the
effector cells T-helper limphocyte recruits more macro-
phage to eliminate phagocytozed microbes. In this
process, the cytokines were also released and further
activates yet macrophages, activates, proliferates, and
differentiate T and B lymphocytes, that leads to
inflammation (Abbas et al 2007). Consequently, the
latency time for hyperalgesia response on CFA induced
rats where shorter than the control (p = 0.019). While
this can be acute inflammation phase, the expression of
NK-1 receptors in the joint suggest that SP were already
involved and there has been repeated stimulation of
nerve endings by previous cytokines. Thus the inflam-
mation is no longer in acute phase but leading to its
chronic phase.
CP-96,345 could not inhibit swelling on the CFA
induced rat joint. This result is in line with previous
study (Han et al 2002). On the other hand the statistical
anylisis mentioned previously, has a very narrow result
to achieve before it becomes significant. Added to this,
the effect of CP-96,345 observed were dose dependent
manner, as seen in previous study (Lembeck et al 1992)
the higher the dose, the more significant the effect. Thus
there was a possibility that the dose was not enough, as
the concentration applied in present study was the
lowest working concentration of CP-96,345 for
neurogenic inflammation (Bhatia et al 2006, Lembeck et
al 1992, Pothoulakis et al 1994, Snider et al 1991,
Nessler et al 2006).
Immunohistochemical staining revealed NK-1 receptors
expression present on both control and CFA induced
rats, only with higher intensity on CFA induced rats.
This could mean that NK-1 receptors is also expressed
even at basal condition. Although, we could not ignore
the possibility that the NK-1 receptors expression on
normal rats were the result of repeated stimulation of
heat stimulus during hot-plate test. Histological findings
confirmed there was proliferation and hypertrophy on
synovial lining in the joint of CFA indiced rats
compared to that of control’s. Unfortunately, CP-96,345
could not alter the joint destruction progress, as the
histology observation revealed the same RA character-
istics found in all of treatment groups.
CONCLUSION
Taken together, present study provides evidence on the
involvement of local NK-1 receptor in the signaling
pathway leading acute inflammation phase into the
chronic state of rheumatoid arthritis and the possibility
of using NK-1 antagonist as local therapy in chronic
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pain associated with rheumatoid arthritis by attenuating
hyperalgesia response.
REFERENCES
Abbas AK, Lichtman AH, Pillai S (2007). Cellular and
Molecular Immunology, Philadelphia, Saunders
Elsevier, p 5-12
Aggarwal A and Myles A (2013). Inflammatory
cascades in autoimmune disease. In: Roy S, Bagchi D,
Raychaudhuri SP (eds). Chronic Inflammation,
Molecular Pathophysiology, Nutritional and
Therapeutic Interventions, Florida, CRC Press, p 213-
220
Aloisi AM and Bonifazi M (2006). Sex hormones,
central nervous system and pain. Hormones and
Behavior 50, 1-7
Austin PJ and Taylor GM (2010). The neuro-immune
balance in neuropathic pain: involment of
inflammatory immune cells, immune-like glial cells
and cytokines. Journal of Neuroimmunology 229, 26-
50
Bhatia M and Lau HY (2006). The effect of CP96,345
on the expression of tachykinins and neurokinins
receptors in acute pancreatitis. Journal of Pathology
208, 364-371
Bhatia M, Moochhala S, Koh YH (2012). Activation of
neurokinin-1 receptors up-regulates substance P and
neurokinin-1 receptor expression in murine pancreatic
acinar cells. Journal of Molecular Medicine 16, 1582-
1592
Bhatia M, Tamizhselvi R, Ramnath RD, Sun J (2009).
Role of protein kinase C and phosponoisitide 3-
kinase-Akt in substance P-induced proinflammatory
pathways in mouse machrophages. The Journal of The
Federation of American Societies for Experimental
Biology 23, 997-1010
Brain SD and Keeble JE (2004). A role for substance P
in arthritis. Neuroscience Letters 361, 176-179
Breedveld FC and Kalden JR (2004). Appropriate and
effective management of rheumatoid arthritis. Annals
of Rheumatic Disease 63, 627-633
Cases RP, Sanz NG, Palao CM, Montiel AF (2005).
Functional aspects and mechanisms of TRPV1
involment in neurogenic inflammation that leads to
thermal hyperalgesia. European Journal of Physiology
451, 151-159
Davis AJ and Perkins MN (1996). Substance P and
capsaicin-induced mechanical hyperalgesia in the rat
knee joint; the involment of bradykinin B1 and B2
receptors. British Journal of Pharmacology 118, 2206-
2212
Dickenson A (1999). The roles of spinal receptors in
nociceptive responses. In: Brain SD and Moore PK
(eds). Pain and Neurogenic Inflammation, New York,
Springer, p 23-38
Emery P (2011). Pocket Reference to Early Rheumatoid
Arthritis, London, Springer Healtcare Ltd, p 3-51
Geppeti P, Materazzi S, Nicoletti P, Trevisani M (2006).
In vivo models of neurogenic inflammation. In:
Stevenson CS, Marshall LA, Morgan DW (eds). In
Vivo Models of Inflammation, Vol 1, Switzerland,
Birkhäuser Basel, p 121-135
Gerhardt WK abd Schmidtko A (2011). A novel
signaling pathway that modulates inflammatory pain.
The Journal of Neuroscience 3, 798-800
Hong SK, Han JS, Min SS, Hwang JM, Kim YI, Na HS,
Yoon YW, Han HC (2002). Local neurokinin-1
receptor in the knee joint contributes to the induction,
but not maintenance, of arthritic pain in the rat.
Neuroscience Letters 322, 21-24
Johnson K and Bolay H (2005). Neurogenic
inflammatory mechanisms. In: Olesen J, Tfelt-Hansen
P, Welch K, Goadsby PJ, Ramadan N. Headaches,
Philadelphia, Lippincot Williams & Wilkins, p 311
Krause JE, Takeda Y, Hershey AD (1992). Structure,
functions, and mechanisms of substance P receptor
action. Journal of Investigative Dermatology 98, 2S-
7S
Lee YC and Hasset AL (2011). Pain in rheumatoid
arthritis. Available from http://www.the-
rheumatologist.org/article/pain-in-rheumatoid-
arthritis/. Accessed 10 November, 2014
Lembeck F, Donnerer J, Tsuchiya M, Nagahisa A
(1992). The non-peptide tachykinin antagonist, CP-
96,345 is a potents inhibitor of neurogenic
inflammation. British Journal of Pharmacology 105,
527-530
Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen
F, Brueck W, Hemmer B, Sommer N (2006).
Suppression of autoimmune encephalomyelitis by a
neurokinin-1 receptor antagonist - a putative role for
substance P in CNS inflammation. Journal of
Neuroimmunology 179, 1-8
O'Connor TM, O'Connell J, O'Brien DI, Goode T,
Bredin CP, Shanahan F (2004). The role of substance
p in inflammatory disease. Journal of Cellular
Physiology 201, 167-180
Peterson M, Svärdsudd K, Appel L, Engler H, Aarnio
M, Gordh T, Långström B, Sörensen J (2013). PET-
scan shows peripherally increased neurokinin 1
receptor availability in chronic tennis elbow:
visualizing neurogenic inflammation? PloS ONE 8,
e75859
Pothoulakis C, Castagliuolo I, Lamont JT, Jaffer A,
O'Keane JC, Snider RM, Leeman SE (1994). CP-
96,345, a substance P antagonist inhibits rat intestinal
responses to clostridium difficile toxin A but not
cholera toxin. Proceedings of the National Academy
of Sciences 91, 947-951
Folia Medica Indonesiana Vol. 52 No. 2 April - June 2016 : 87-93
93
Reedquist KA and Tak PP (2012). Signal transduction
pathways in chronic inflammatory autoimmune
disease: small GTPases. The Open Rheumatology
Journal 6, 259-272
Ren K and Dubner R (2010). Interactions between the
immune and nervous systems in pain. Nature
Medicine 16, 1267-1276
Richardson JD and Vasko MR (2002). Cellular
mechanisms of neurogenic inflammation. The Journal
of Pharmacology and Experimental Therapeutics 302,
839-845
Shrikhande SV, Friess H, di Mola FF, Tempia-Caliera
A, Garcia JRC, Zhu Z, Zimmermann A, Büchler MW
(2001). NK-1 receptor gene expression is related to
pain in chronic pancreatitis. Pain 91, 209-217
Snider RM, Longo KP, Drozda SE, Lowe JA, Leeman
SE (1991). Effect of CP-96,345 a nonpeptide
substance P receptor antagonist on salivation in rats.
Proceedings of National Academy of Sciences 88,
10042-10044
Teodoro FC, TroncoJr MF, Zampronio AR, Martini AC,
Rae GA, Chichorro JG (2013). Peripheral substance P
and neurokinin-1 receptors have a role in
inflmammatory and neurophatic orofacial pain
models. Neuropeptides 47, 199-206
Tsuda M, Masuda T, Tozaki-Saitoh H, Inoue K (2013).
P2X4 receptors and neuropathic pain. Frontiers in
Cellular Neuroscience 7, 167-172
Vashist H, Gupta A, Jindal A, Jalhan S (2012). animal
models for arhtritis-a review. International Journal of
recent Advances in Pharmaceutical Research 2, 20-25
Xu XJ, Dalsgaard CJ, Maggi CA, Wiesenfeld-Hallin Z
(1992). NK-1, but not NK-2, tachykinin receptors
mediate plasma extravasation induced by antidromic
C-fiber stimulation in rat hindpaw: demonstrated with
the NK-1 antagonist CP-96,345 and the NK-2
antagonist men 10207. Neuroscience Letters 139, 249-
252
